Evidence map›Paper›PMID 40572682›Full record

Observational studyMedicina (Kaunas, Lithuania)2025

Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study.

Yuhei Kurata, Atsuto Mouri, Hisao Imai, Satoshi Endo, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi and 4 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuhei KurataDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-1298, Saitama, Japan.
Atsuto MouriDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-1298, Saitama, Japan.
Hisao ImaiDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-1298, Saitama, Japan.ORCID 0000-0003-3097-4255
Satoshi EndoDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Gunma, Japan.
Kasumi TsukamotoDivision of Respiratory Medicine, National Hospital Organization Disaster Medical Center, Tachikawa 190-0014, Tokyo, Japan.
Kenji MasakiDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-1298, Saitama, Japan.
Kosuke HashimotoDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-1298, Saitama, Japan.
Yu MiuraDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-1298, Saitama, Japan.
Ayako ShionoDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-1298, Saitama, Japan.
Ou YamaguchiDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-1298, Saitama, Japan.
Junichi NakagawaDivision of Respiratory Medicine, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, Gunma, Japan.
Kyoichi KairaDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-1298, Saitama, Japan.ORCID 0000-0001-5548-7686
Kunihiko KobayashiDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-1298, Saitama, Japan.ORCID 0000-0002-6468-9068
Hiroshi KagamuDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-1298, Saitama, Japan.ORCID 0000-0003-4523-8517

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungIpilimumabLung NeoplasmsNivolumabAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalFemaleHumansJapanMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeAntineoplastic Agents, ImmunologicalIpilimumabNivolumabadvanced non-small cell lung cancerimmune checkpoint inhibitoripilimumabnivolumabpostoperative recurrence

Identifiers

PMID40572682
PMCPMC12195084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.